Want to see AIMD full AI Analyst Report?
AIMD Stock Chart & Stats
$2.28
$0.28(14.00%)
At close: 4:00 PM EST
$2.28
$0.28(14.00%)
Day’s Range― - ―
52-Week Range$1.26 - $4.50
Previous CloseN/A
Volume448.92K
Average Volume (3M)78.00K
Market Cap
$15.94M
Enterprise Value$20.21M
Total Cash (Recent Filing)$2.84M
Total Debt (Recent Filing)$13.81M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding8,524,542
10 Day Avg. Volume93,591
30 Day Avg. Volume77,998
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue1.12K
Enterprise Value/Gross Profit-4.24
Enterprise Value/Ebitda-2.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI Nose PlatformA proprietary sensing and AI platform creates durable differentiation: sensors plus VOC analytics can be applied across indications, enabling recurring device/software data streams, licensing, and long-term product moats versus single-use assays if the technology proves reliable and validated.
High Gross Margins On Existing RevenueElevated gross margins indicate the company's core sensing/analysis model has strong incremental economics. If revenue scales, those margins support operating leverage, faster path to profitability, and better returns on R&D and commercialization investments over multiple quarters.
Multi-application Market OptionalityMultiple commercial pathways—point-of-care diagnostics, therapeutic/drug development support, licensing—provide structural optionality. This diversification can reduce single-market dependency and allow the firm to pursue the fastest route to sustainable revenue and partner deals over months to years.
Bears Say
Extremely Low And Declining RevenueRevenue near zero and an ~85% decline show limited commercial traction and weak product-market fit. Over a multi-month horizon this constrains ability to scale operations, undermines confidence of partners/customers, and makes fixed costs and R&D spending unsustainable without external capital.
Sustained Cash BurnOngoing negative operating and free cash flow indicate the company must access external funding to continue development and commercialization. Persistent burn increases dilution or credit risk, may delay clinical/commercial milestones, and limits strategic flexibility over the next several quarters.
Elevated Leverage Vs. Shrinking EquityHigh debt relative to a shrinking equity base raises refinancing and covenant risk for a loss-making biotech. Servicing debt constrains R&D and commercialization spend, increases bankruptcy/dilution risk if revenues don't materialize, and reduces strategic optionality over months.
Ainos News
AIMD FAQ
What was Ainos’s price range in the past 12 months?
Ainos lowest stock price was $1.26 and its highest was $4.50 in the past 12 months.
What is Ainos’s market cap?
Ainos’s market cap is $15.94M.
When is Ainos’s upcoming earnings report date?
Ainos’s upcoming earnings report date is Aug 18, 2026 which is in 45 days.
How were Ainos’s earnings last quarter?
Ainos released its earnings results on May 13, 2026. The company reported -$0.408 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.408.
Is Ainos overvalued?
According to Wall Street analysts Ainos’s price is currently Overvalued.
Does Ainos pay dividends?
Ainos does not currently pay dividends.
What is Ainos’s EPS estimate?
Ainos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ainos have?
Ainos has 8,524,542 shares outstanding.
What happened to Ainos’s price movement after its last earnings report?
Ainos reported an EPS of -$0.408 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.585%.
Which hedge fund is a major shareholder of Ainos?
Currently, no hedge funds are holding shares in AIMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ainos
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Soligenix
―
Chemomab Therapeutics
―
―
FibroBiologics, Inc.
―
Ownership Overview
41.69% Insiders
0.37% Mutual Funds
0.19% Other Institutional Investors
57.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---